| Literature DB >> 28043417 |
Noman Ibna Amin Patwary1, Md Saiful Islam1, Md Sohel1, Ismot Ara2, Mohd Omar Faruk Sikder1, Shah Md Shahik3.
Abstract
BACKGROUND: Human Adenoviruses are divided into 7 species of Human Adenovirus A to G based on DNA genome homology. The Human Adenovirus E (HAdVs-E) genome is a linear, double-stranded DNA containing 38 protein-coding genes. Wild-type adenoviruses type E, are linked to a number of slight illnesses. The most important part of HAdVs-E is E3 CR1-beta protein which controls the host immune response and viral attachment.Entities:
Keywords: 3D structure prediction; B cell epitope; Human Adenoviruses E; T cell epitope; Vaccine
Mesh:
Substances:
Year: 2016 PMID: 28043417 PMCID: PMC6138513 DOI: 10.1016/j.bj.2016.11.004
Source DB: PubMed Journal: Biomed J ISSN: 2319-4170 Impact factor: 4.910
Fig. 1Secondary structure of E3 CR1-beta protein of HAdVs-E.
Fig. 2Predicted 3-dimensional structure of the E3 CR1-beta protein of HAdVs using Homology Modelling.
Fig. 3Ramachandran plot showing residues in the most favorable region and disallowed regions.
Fig. 4Z-score showing the quality of the 3D structure.
Predicted B-cell epitopes.
| Position | Epitopes + antigenicity | Score | TMHMM |
|---|---|---|---|
| 133 | TTKLTTTTSTTL | 0.7851 | Inside |
| 111 | LDPTTPRTTTKH | 0.8499 | Inside |
| 170 | PLPTTPSEQIPR | 0.4627 | Outside |
| 72 | YYSCTNNNITLL | 0.1904 | Inside |
| 170 | VALLQNGENNSS | 0.4692 | Outside |
| 92 | TYYGTNFNTEQD | 1.1681 | Inside |
| 98 | LCKGNQRPTQRS | 1.0843 | Inside |
| 18 | NSFDHKNVTAYV | 0.3329 | Inside |
| 35 | LTGYQSHQRVSW | 0.5302 | Inside |
| 202 | MYYACYYRKHRL | −0.1409 | Inside |
Discontinuous epitope prediction from the 3D structure of the E1 protein using DiscoTop online server.
| Position | Residue | Contact number | Propensity score | DiscoTop score |
|---|---|---|---|---|
| 14 | SER | 1 | −3.958 | −3.617 |
| 40 | GLN | 8 | −0.799 | −1.627 |
| 41 | GLY | 0 | 0.746 | 0.66 |
| 42 | LYS | 15 | −0.923 | −2.542 |
| 43 | SER | 2 | −2.643 | −2.569 |
| 80 | PRO | 0 | −3.45 | −3.054 |
| 94 | THR | 0 | −3.929 | −3.478 |
| 106 | ILE | 5 | −3.14 | −3.354 |
Fig. 5Predicted B-cell epitopic regions of the E3 CR1-beta protein 3D structure. B-cell epitopic regions are shown in yellow color.
MHC class I binding peptides on the basis of antigenicity.
| Position | Peptide | Allele | Score |
|---|---|---|---|
| 3 | SVTAIIYFL | HLA-A1/HLA-A2/HLA-A*0201/HLA-A*0205/HLA-A*1101/HLA-A24/HLA-A3/HLA-A*3101/HLA-A*3302/HLAA68.1/HLA-A20/HLA-A2.1/HLA-B14/HLA-B*2702/HLA-B*2705/HLA-B*3701/HLA-B*3801/HLA-B*3901/HLA-B*3902/HLA-B*4403/HLA-B*5102/HLA-B*5103/HLA-B*5201/HLA-B*5401/HLA-B*51/HLA-B62/HLA-B7/HLA-B*0702/HLA-B8/HLA-Cw*0301/HLA-Cw*0401/HLA-Cw*0602/HLA-Cw*0702/MHC-Db/MHC-Db/MHC-Dd/MHC-Kb/MHC-Kd/MHC-Kk/MHC-Ld | 0.2046 |
| 136 | LTTTTSTTL | HLA-A1/HLA-A2/HLA-A*0205/HLA-A*1101/HLA-A24/HLA-A3/HLA-A*3101/HLA-A*3302/HLA-A20/HLA-A2.1/HLA-B14/HLA-B*2705/HLA-B*3901/HLA-B*3902/HLA-B40/HLA-B*4403/HLA-B*5102/HLA-B*5103/HLA-B*5301/HLA-B*5401/HLA-B*51/HLA-B*5801/HLA-B60/HLA-B61/HLA-B62/HLA-B7/HLA-B*0702/HLA-B8/HLA-Cw*0301/HLA-Cw*0401/HLA-Cw*0602/MHC-Db/MHC-Db/MHC-Kb/MHC-Kd/MHC-Ld | 0.7174 |
| 145 | AVTSQATTE | HLA-A68.1 | 0.6511 |
| 148 | SQATTENEL | HLA-A2/HLA-A*0201/HLA-A*0205/HLA-A*1101/HLA-A24/HLA-A3/HLA-A*3101/HLA-A*3302/HLA-A20/HLA-B*2702/HLA-B*2705/HLA-B*3901/HLA-B*3902/HLA-B40/HLA-B*4403/HLA-B*5102/HLA-B*5201/HLA-B*5401/HLA-B60/HLA-B61/HLA-B62/HLA-B7/HLA-B*0702/HLA-B8/HLA-Cw*0401/HLA-Cw*0602/HLA-Cw*0702/MHC-Db/MHC-Db/MHC-Kd/MHC-Ld | 0.5100 |
| 149 | QATTENELV | HLA-A1/HLA-A20/HLA-A2.1/HLA-B*4403/HLA-B*5102/HLA-B*5103/HLA-B*5201/HLA-B*5301/MHC-Kd/MHC-Ld | 0.5098 |
| 152 | TENELVALL | HLA-A2/HLA-A*0201/HLA-A*0205/HLA-A2.1/HLA-B*2702/HLA-B*2705/HLA-B*3701/HLA-B40/HLA-B*5301/HLA-B*5401/HLA-B*51/HLA-B*5801/HLA-B60/HLA-B61/HLA-B*0702/HLA-Cw*0301/HLA-Cw*0401/HLA-Cw*0602/HLA-Cw*0702/MHC-Db/MHC-Dd/MHC-Kb/MHC-Kk/ | 0.4766 |
MHC class II binding peptides on the basis of antigenicity.
| Position | Peptide | Allele | Score |
|---|---|---|---|
| 190 | VVCMVIIIL | DRB1_0701/DRB1_0703/DRB1_0801/DRB1_0802/DRB1_0804/DRB1_0806/DRB1_0817/DRB1_1104/DRB1_1106/DRB1_1311/DRB1_1321/DRB1_1501/DRB1_1502/DRB1_1506/DRB5_0101/DRB5_0105 | 0.7975 |
| 189 | VVVCMVIII | DRB1_0101/DRB1_0102/DRB1_0301/DRB1_0305/DRB1_0306/DRB1_0307/DRB1_0308/DRB1_0309/DRB1_0311/DRB1_0402DRB1_0404/DRB1_0423/DRB1_0701/DRB1_0703/DRB1_0801/DRB1_0802/DRB1_0804/DRB1_0806/DRB1_0813/DRB1_0817/DRB1_1101/DRB1_1102/DRB1_1104/DRB1_1106/DRB1_1107/DRB1_1114/DRB1_1120/DRB1_1121/DRB1_1128/DRB1_1301/DRB1_1302/DRB1_1304/DRB1_1305/DRB1_1307/DRB1_1311/DRB1_1322/DRB1_1323/DRB1_1327/DRB1_1328/DRB1_1501/DRB1_1502/DRB1_1506. | 0.6958 |
| 194 | VIIILCMMY | DRB1_0101/DRB1_0102/DRB1_0301/DRB1_0309/DRB1_0402/DRB1_0404/DRB1_0405/DRB1_0408/DRB1_0410/DRB1_0421/DRB1_0423/DRB1_1101/DRB1_1104/DRB1_1106/DRB1_1107/DRB1_1128/DRB1_1305/DRB1_1307/DRB1_1311/DRB1_1321/DRB5_0101/DRB5_0105/ | 0.7414 |
| 193 | MVIIILCMM | DRB1_0102/DRB1_0301/DRB1_0305/DRB1_0306/DRB1_0307/DRB1_0308/DRB1_0309/DRB1_0311/DRB1_0421/DRB1_0801/DRB1_0802/DRB1_0804/DRB1_0806/DRB1_0813/DRB1_0817/DRB1_1101/DRB1_1102/DRB1_1104/DRB1_1106/DRB1_1107/DRB1_1120/DRB1_1121/DRB1_1128/DRB1_1301/DRB1_1302/DRB1_1304/DRB1_1305/DRB1_1307/DRB1_1311/DRB1_1321/DRB1_1322/DRB1_1327/DRB1_1328/DRB1_1501/DRB1_1502/DRB1_1506/ | 0.3887 |
| 46 | YWFDKKNTA | DRB1_0305/DRB1_0306/DRB1_0307/DRB1_0308/DRB1_0309/DRB1_0311/DRB1_1107 | 1.1651 |
| 81 | LLQVTKQYS | DRB1_0306/DRB1_0307/DRB1_0308/DRB1_0311/DRB1_1307 | 0.8119 |
| 13 | LGFINSFDH | DRB1_0402/DRB1_0404/DRB1_0405/DRB1_0408/DRB1_0410/DRB1_0423 | −0.6980 |
| 79 | ITLLQVTKQ | DRB1_0404/DRB1_0405/DRB1_0408/DRB1_0410/DRB1_0423/DRB1_0813/DRB1_1102/DRB1_1121/DRB1_1322/ | 0.9021 |
| 206 | YYRKHRLNN | DRB1_0801/DRB1_0802/DRB1_0804/DRB1_0806/DRB1_0813/DRB1_0817/DRB1_1114/DRB1_1120/DRB1_1302/DRB1_1304/DRB1_1321/DRB1_1323/ | 0.3813 |
| 207 | YRKHRLNNK | DRB1_0426/DRB1_1102/DRB1_1114/DRB1_1120/DRB1_1121/DRB1_1302/DRB1_1322/DRB1_1323 | 0.9009 |
| 7 | IYFLGLLGF | DRB1_1128/DRB1_1301/DRB1_1305/DRB1_1327./DRB1_1328 | 0.9583 |
Epitope conservancy result of predicting epitopes.
| Peptide | Epitope conservancy analysis result |
|---|---|
| SVTAIIYFL | 33.33% |
| LTTTTSTTL | 67.43% |
| AVTSQATTE | 33.33% |
| SQATTENEL | 44.44% |
| QATTENELV | 44.44% |
| TENELVALL | 33.33% |
| VVCMVIIIL | 33.33% |
| VVVCMVIII | 33.33% |
| VIIILCMMY | 33.33% |
| MVIIILCMM | 33.33% |
| YWFDKKNTA | 70.32% |
| LLQVTKQYS | 33.33% |
| LGFINSFDH | 33.33% |
| ITLLQVTKQ | 44.44% |
| YYRKHRLNN | 22.22% |
| YRKHRLNNK | 22.22% |
| IYFLGLLGF | 33.33% |